ANDA Approval Times Get Optimistic Estimate In Budget Request
Executive Summary
US FDA has historically overestimated generic review performance in budget requests, but recently underestimated the number of ANDAs it expects to approve.
You may also be interested in...
ANDA Median Approval Times Still Rising, But What Does It Mean?
First quarterly report of median US generic drug times shows longer time to approval than previous estimates, but that may not tell stakeholders much.
ANDA Median Approval Times Still Rising, But What Does It Mean?
First quarterly report of median US generic drug times shows longer time to approval than previous estimates, but that may not tell stakeholders much.
US FDA Wants To Predict ANDA Complete Response Responses
Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.